Rockwell to Buy Vantive Dialysis Assets for Up to $170 Million

By Daniel Okafor

Rockwell Medical has agreed to pay $125 million for Vantive’s hemodialysis assets, with contingent consideration of up to $45 million lifting the maximum to $170 million before customary adjustments. Rockwell announced the agreement in early November 2026.

Rockwell develops, manufactures and distributes hemodialysis products for dialysis providers. According to Rockwell, hemodialysis treats patients with kidney failure by removing waste products and excess fluid from the blood.

Rockwell’s existing business centers on dialysis concentrates and related products. The agreement would extend that product range into equipment and services. It covers Vantive’s hemodialysis concentrates, equipment, water treatment and related services businesses.

The added portfolio includes hemodialysis machines, including the AK-98 platform, water treatment systems, consumables and technical services. The deal also adds Vantive’s Medolla, Italy manufacturing campus. The combination would expand Rockwell’s participation across the dialysis treatment process.

What does Rockwell gain from the acquisition?

The roughly one-million-square-foot facility sits in the Mirandola Biomedical District. Rockwell describes the district as an established medical technology manufacturing region. Vantive’s campus manufactures dry concentrate cartridges, dialysis machines, water treatment systems, equipment components and related consumables.

Rockwell expects the site to provide substantial manufacturing capacity and technical expertise. The company also expects the acquisition to expand its geographic presence and relationships with dialysis providers. Together with Vantive’s global infrastructure, the acquired operations would create a more diversified healthcare products business with a broader manufacturing footprint and product portfolio.

Rockwell believes equipment and services could provide recurring revenue streams that complement its concentrates business. The company also sees opportunities to strengthen research and development and support further product innovation. Rockwell says the transaction positions it for a larger role in the global hemodialysis market.

Mark Strobeck, president and CEO of Rockwell Medical, said:

“Acquiring Vantive’s hemodialysis assets and associated operations represents a transformative step in Rockwell Medical’s evolution and directly advances the strategy we have been executing over the past several years.

This transaction has the potential to accelerate the next phase of our growth by adding meaningful product breadth, global distribution, manufacturing and R&D infrastructure, technical service capabilities and recurring revenue streams that would take years to build organically.

We believe the combined businesses will expand our ability to serve dialysis providers and patients across the global hemodialysis ecosystem and creates a stronger platform for growth, innovation and long-term value creation for customers, patients, employees and shareholders.”

How does the deal’s financing work?

The purchase agreement sets an aggregate base price of $125 million, subject to customary adjustments. Vantive will provide two $50 million term loans, while Rockwell will issue a $25 million convertible note to the seller as part of the financing. Vantive may receive up to $45 million in additional contingent consideration if specified revenue and EBITDA milestones are achieved.

• Maximum consideration: $170 million before customary purchase price adjustments.
• Convertible note: The initial conversion price will reflect a 100% premium to Rockwell’s applicable 15-day volume-weighted average share price, calculated under the transaction documents.
• Expected close: Mid-2027, subject to regulatory approvals and other closing requirements.

What supports the revenue forecast?

Rockwell expects the expanded business to generate $400 million to $450 million in annual revenue. The company says that its revenue estimate depends on stated assumptions involving operating performance, currency exchange rates, market conditions and successful integration of the acquired operations.

Rockwell has withdrawn its previously issued 2026 guidance for net sales, gross margin, adjusted EBITDA and operating cash flow. It attributed the withdrawal to anticipated transaction and financing expenses.

The proposed acquisition also introduces operational complexity. Rockwell will need to integrate manufacturing facilities, distribution systems, employees, customer relationships and regulatory requirements as it expands into new products and international markets.

How will Vantive manage the transition?

Chris Toth, CEO of Vantive, said:

“Our priority has been to identify the right buyer that understands the importance of continuity for customers, patients and employees.

Rockwell Medical’s singular focus on hemodialysis, operating experience and commitment to investing in people and capabilities provide a strong foundation for the next chapter of these hemodialysis assets and operations.

We believe this transaction will build on the progress our teams have made, while helping to create new and expanded opportunities for customers, patients and employees, and we are committed to supporting a smooth transition.”

Aquilo Partners serves as Rockwell’s exclusive financial advisor. Gibson Dunn provides legal counsel to Rockwell. Perella Weinberg Partners and Barclays advise Vantive, and Kirkland & Ellis provides legal counsel to Vantive.

Rockwell’s integration work begins after closing. The company must integrate manufacturing, distribution, employees, customer relationships and regulatory requirements while converting its $400 million to $450 million annual revenue estimate into actual revenue.